Latest news
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales - theglobeandmail.comtheglobeandmail.com · Wed, 05 Aug 2026 16:50:00 GMTACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating - TipRanksTipRanks · Wed, 05 Aug 2026 10:49:07 GMTNeuren reports record DAYBUE sales as royalties rise and global expansion nears - BiotechDispatchBiotechDispatch · Wed, 05 Aug 2026 09:32:35 GMTNeuren Pharmaceuticals Stock Soars 17.5% After Record DAYBUE Sales Growth and Royalty Forecast Boost - International Business Times AustraliaInternational Business Times Australia · Wed, 05 Aug 2026 06:18:02 GMTNEU:ASX Announcement - Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded - 05 Aug 2026 - Market IndexMarket Index · Wed, 05 Aug 2026 04:11:25 GMTNeuren Pharmaceuticals Reports Record Q2 DAYBUE Sales, Upgrades Full-Year Royalty Forecast - SharecafeSharecafe · Wed, 05 Aug 2026 01:00:30 GMTNeuren (ASX:NEU) Reports Continued Growth in DAYBUE Commercial Performance - KalkineKalkine · Wed, 05 Aug 2026 00:45:00 GMTNeuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade - The Motley Fool AustraliaThe Motley Fool Australia · Wed, 05 Aug 2026 00:19:28 GMT